Literature DB >> 26515235

Dyslipidemia and its association with meibomian gland dysfunction.

Puneet S Braich1, Mary K Howard2, Jorawer S Singh3.   

Abstract

Abnormal serum lipid levels significantly increase the risk for cardiovascular disease. Furthermore, abnormal compositions of cholesterol in glandular secretions have been hypothesized as an etiology for meibomian gland dysfunction, yet this relationship has not been well studied in clinical settings. The primary purpose of this study was to determine if there is an association between dyslipidemia and meibomian gland dysfunction (MGD). The secondary purpose was to identify the factors, if any, that play a role in this association. A case-control study was performed between October 2013 and February 2015 which recruited 109 patients with MGD and 115 control patients without MGD. All participants were of Indian descent and had no history of dyslipidemia. Basic demographic information was collected as well as fasting levels of serum glucose, creatinine, triglycerides, total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). To calculate differences between groups, Z test or Student t test were used. A stepwise logistic regression model was used to calculate the estimates of odds ratios (ORs), where MGD was the dependent variable, making the independent variables consist of sex, age, body mass index (BMI), triglycerides ≥150 mg/dL, total cholesterol ≥200 mg/dL, LDL ≥130 mg/dL, or HDL ≤40 mg/dL, serum glucose, and serum creatinine. Dyslipidemia, defined by either a fasting total cholesterol level of ≥ 200 mg/dL, triglycerides ≥150 mg/dL, LDL ≥130 mg/dL, or HDL ≤40 mg/dL, was detected in 70 cases (64 %) and 21 controls (18 %), P < 0.001. Mean levels of triglycerides, total cholesterol, LDL, and HDL were 98.5 ± 42.1, 203.1 ± 13.2, 126.1 ± 10.2, and 53.3 ± 4.2 mg/dL, respectively, in cases and 82.3 ± 36.5, 156.6 ± 14.5, 92.2 ± 12.4, 45.8 ± 2.6 mg/dL, respectively, in controls. All differences were statistically significant (P < 0.05). MGD was significantly associated with age >65 years (OR 2.1; 95 % CI 1.2-3.2, P = 0.04), serum triglyceride concentration ≥150 mg/dL (OR 3.2; 95 % CI 1.9-4.4; P = 0.03), total cholesterol ≥200 mg/dL (OR 14.3; 95 % CI 8.2-20.7, P < 0.01), and LDL ≥130 mg/dL (OR 9.1; 95 % CI 6.6-13.2, P < 0.01). Adults from northern rural India with MGD are more likely to have abnormal serum lipid levels compared to age- and sex-matched adults without MGD. Eye care providers may have a role in discovering undiagnosed dyslipidemia, an important risk factor for cardiovascular illness.

Entities:  

Keywords:  Dyslipidemia; Hypercholesterolemia; Meibomian gland dysfunction

Mesh:

Substances:

Year:  2015        PMID: 26515235     DOI: 10.1007/s10792-015-0149-4

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  34 in total

1.  Counting the dead and what they died from: an assessment of the global status of cause of death data.

Authors:  Colin D Mathers; Doris Ma Fat; Mie Inoue; Chalapati Rao; Alan D Lopez
Journal:  Bull World Health Organ       Date:  2005-03-16       Impact factor: 9.408

2.  The role of cholesterol in chronic blepharitis.

Authors:  W E Shine; J P McCulley
Journal:  Invest Ophthalmol Vis Sci       Date:  1991-07       Impact factor: 4.799

3.  Association of dyslipidemia in moderate to severe meibomian gland dysfunction.

Authors:  Adam H Dao; Jordan D Spindle; Blake A Harp; Arun Jacob; Alice Z Chuang; Richard W Yee
Journal:  Am J Ophthalmol       Date:  2010-07-08       Impact factor: 5.258

4.  Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation.

Authors:  S C Pflugfelder; S C Tseng; O Sanabria; H Kell; C G Garcia; C Felix; W Feuer; B L Reis
Journal:  Cornea       Date:  1998-01       Impact factor: 2.651

5.  Effects of pictograms in educating 3 distinct low-literacy populations on the use of postoperative cataract medication.

Authors:  Puneet S Braich; David R Almeida; Simon Hollands; Mary T Coleman
Journal:  Can J Ophthalmol       Date:  2011-05-27       Impact factor: 1.882

6.  Improving awareness, identification, and management of meibomian gland dysfunction.

Authors:  Gary N Foulks; Kelly K Nichols; Anthony J Bron; Edward J Holland; Marguerite B McDonald; J Daniel Nelson
Journal:  Ophthalmology       Date:  2012-10       Impact factor: 12.079

7.  A Clinical Study of Subtype-based Prevalence of Dry Eye.

Authors:  Aditya Rege; Varsha Kulkarni; Neelam Puthran; Tejaswini Khandgave
Journal:  J Clin Diagn Res       Date:  2013-10-05

8.  Role of wax ester fatty alcohols in chronic blepharitis.

Authors:  W E Shine; J P McCulley
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-12       Impact factor: 4.799

Review 9.  Rethinking dry eye disease: a perspective on clinical implications.

Authors:  Anthony J Bron; Alan Tomlinson; Gary N Foulks; Jay S Pepose; Christophe Baudouin; Gerd Geerling; Kelly K Nichols; Michael A Lemp
Journal:  Ocul Surf       Date:  2014-02-13       Impact factor: 5.033

Review 10.  Meibomian gland disease. Classification and grading of lid changes.

Authors:  A J Bron; L Benjamin; G R Snibson
Journal:  Eye (Lond)       Date:  1991       Impact factor: 3.775

View more
  13 in total

Review 1.  Depression and burden among the caregivers of visually impaired patients: a systematic review.

Authors:  Robin K Kuriakose; Zainab Khan; David R P Almeida; Puneet S Braich
Journal:  Int Ophthalmol       Date:  2016-07-29       Impact factor: 2.031

Review 2.  Dyslipidemia and its Association with Meibomian Gland Dysfunction: A Systematic Review.

Authors:  Robin K Kuriakose; Puneet S Braich
Journal:  Int Ophthalmol       Date:  2017-07-07       Impact factor: 2.031

3.  Association of Dry Eye Disease With Dyslipidemia and Statin Use.

Authors:  Khalid M Aldaas; Omar M Ismail; Judi Hakim; Eric D Van Buren; Feng-Chang Lin; Joshua S Hardin; Jay J Meyer
Journal:  Am J Ophthalmol       Date:  2020-05-12       Impact factor: 5.258

4.  Asymptomatic Meibomian Gland Dysfunction and Cardiovascular Disease Risk Factors in a Middle-Aged Population in Taiwan - A Cross-sectional Analysis.

Authors:  Alexander Chen; Hung-Ta Chen; Hung-Chi Chen; Yi-Tsun Chen; Yih-Hsiou Hwang; Chi-Chin Sun; Ching-Hsi Hsiao; David Hui-Kang Ma; Wei-Chi Wu; Chi-Chun Lai
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

5.  Assessment of meibomian glands using a custom-made meibographer in dry eye patients in Ghana.

Authors:  Eugene Appenteng Osae; Reynolds Kwame Ablorddepey; Jens Horstmann; David Ben Kumah; Philipp Steven
Journal:  BMC Ophthalmol       Date:  2018-08-16       Impact factor: 2.209

6.  The association between cadmium and lead exposure and blood pressure among workers of a smelting industry: a cross-sectional study.

Authors:  Hyun Chan An; Joo Hyun Sung; Jiho Lee; Chang Sun Sim; Sang Hoon Kim; Yangho Kim
Journal:  Ann Occup Environ Med       Date:  2017-10-04

7.  Relation of Dietary Fatty Acids and Vitamin D to the Prevalence of Meibomian Gland Dysfunction in Japanese Adults: The Hirado-Takushima Study.

Authors:  Shima Fukuoka; Reiko Arita; Takanori Mizoguchi; Motoko Kawashima; Shizuka Koh; Rika Shirakawa; Takashi Suzuki; Satoshi Sasaki; Naoyuki Morishige
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

Review 8.  Meibomian Gland Dysfunction: What Have Animal Models Taught Us?

Authors:  Mingxia Sun; Isabel Y Moreno; Michelle Dang; Vivien J Coulson-Thomas
Journal:  Int J Mol Sci       Date:  2020-11-21       Impact factor: 5.923

9.  Characterization of Meibomian Gland Atrophy and the Potential Risk Factors for Middle Aged to Elderly Patients With Cataracts.

Authors:  Xiaolei Lin; Yue Wu; Yiqin Chen; Yuyu Zhao; Linfeng Xiang; Qi Dai; Yana Fu; Yinying Zhao; Yun-E Zhao
Journal:  Transl Vis Sci Technol       Date:  2020-06-30       Impact factor: 3.283

10.  Association of the severity of meibomian gland dysfunction with dyslipidemia in Indian population.

Authors:  Brahm P Guliani; Abhinav Bhalla; Mayuresh P Naik
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.